Autopsy report · NCT02169284
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
Cause of deathNo reason given
Life of this trial
- Registered 3 months before it started.
- Ran for about 3 years 6 months before it stopped.
- 50 participants enrolled.
- Results were posted on the registry 2 years 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Bladder Carcinoma; Recurrent Bladder Carcinoma
- Interventions
- Erlotinib Hydrochloride; Laboratory Biomarker Analysis; Pharmacological Study; Placebo; Quality-of-Life Assessment; Therapeutic Conventional Surgery
- Participants
- 50
- Sites
- 6
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.